Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Inhalational Therapy for Pulmonary Arterial Hypertension: Current Status and Future Prospects

Volume 27, Issue 4, 2010, pp. 313-370
DOI: 10.1615/CritRevTherDrugCarrierSyst.v27.i4.20
Get accessGet access

ABSTRACT

This review summarizes the pathophysiology and current therapeutic and drug delivery strategies for pulmonary arterial hypertension (PAH), a rare but devastating disorder of the pulmonary circulation affecting 50,000 to 100,000 persons in the United States. Chief clinical features of PAH include increased mean pulmonary arterial pressure (>25 mm Hg) and right ventricular and smooth muscle hypertrophy. A wide variety of agents have been studied for use as anti-PAH drugs, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, to name a few. However, a major shortcoming of anti-PAH medications is their short half-lives, requiring them to be administered via parenteral routes, which lead to undesirable side effects, including systemic vasodilation. Inhalational delivery of anti-PAH drugs provides an attractive alternative to conventional routes, with ease of administration and minimal systemic vasodilation. Recently, the U.S. Food and Drug Administration approved inhalable iloprost (Ventavis®), a prostacyclin analogue, for PAH treatment. Other drugs being studied for their potential in inhalable PAH therapy include PGE1, treprostinil, vasoactive intestinal peptide, and fasudil. Controlled-release inhalable delivery systems for anti-PAH medications have also been proposed to facilitate long-term and selective vasodilation of pulmonary arteries. Extensive studies are warranted to develop safe and effective drug delivery systems that will provide a better quality of life to patients.

CITED BY
  1. Gupta Vivek, Gupta Nilesh, Shaik Imam H., Mehvar Reza, McMurtry Ivan F., Oka Masahiko, Nozik-Grayck Eva, Komatsu Masanobu, Ahsan Fakhrul, Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension, Journal of Controlled Release, 167, 2, 2013. Crossref

  2. Mosgoeller W., Prassl R., Zimmer A., Nanoparticle-Mediated Treatment of Pulmonary Arterial Hypertension, in Nanomedicine - Cancer, Diabetes, and Cardiovascular, Central Nervous System, Pulmonary and Inflammatory Diseases, 508, 2012. Crossref

  3. Arumpanayil Angela, Inhaled Epoprostenol to Support the Severely Hypoxemic Patient With Acute Respiratory Distress Syndrome, Dimensions of Critical Care Nursing, 32, 5, 2013. Crossref

  4. Gupta Nilesh, Ibrahim Hany M., Ahsan Fakhrul, Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension, Journal of Pharmaceutical Sciences, 103, 11, 2014. Crossref

  5. Patel Brijeshkumar, Gupta Nilesh, Ahsan Fakhrul, Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome, European Journal of Pharmaceutics and Biopharmaceutics, 89, 2015. Crossref

  6. Uña Orejón R., Altit Millán E., Aguar Fernández M., Ureta Tolsada M.P., Paraganglioma productor de catecolaminas en una paciente con síndrome de Eisenmenger y ventrículo único. Interés de la administración de óxido nítrico y monitorización hemodinámica mínimamente invasiva, Revista Española de Anestesiología y Reanimación, 63, 3, 2016. Crossref

  7. Vaidya Bhuvaneshwar, Gupta Vivek, Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery, Journal of Controlled Release, 211, 2015. Crossref

  8. Gupta Vivek, Ahsan Fakhrul, Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator, International Journal of Pharmaceutics, 413, 1-2, 2011. Crossref

  9. Shoemaker Ritchie C., House Dennis, Ryan James C., Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings, Health, 05, 03, 2013. Crossref

  10. Dabbagh Ali, Postoperative Respiratory Management in Pediatric Cardiac Surgical Patients, in Congenital Heart Disease in Pediatric and Adult Patients, 2017. Crossref

  11. Hecker Louise, Mechanisms and consequences of oxidative stress in lung disease: therapeutic implications for an aging populace, American Journal of Physiology-Lung Cellular and Molecular Physiology, 314, 4, 2018. Crossref

  12. Ofman Gaston, Tipple Trent E., Antioxidants & bronchopulmonary dysplasia: Beating the system or beating a dead horse?, Free Radical Biology and Medicine, 142, 2019. Crossref

  13. Kwon Yong-Bin, Kang Ji-Hyun, Han Chang-Soo, Kim Dong-Wook, Park Chun-Woong, The Effect of Particle Size and Surface Roughness of Spray-Dried Bosentan Microparticles on Aerodynamic Performance for Dry Powder Inhalation, Pharmaceutics, 12, 8, 2020. Crossref

  14. Gupta Vivek, Gupta Nilesh, Shaik Imam H., Mehvar Reza, Nozik-Grayck Eva, McMurtry Ivan F., Oka Masahiko, Komatsu Masanobu, Ahsan Fakhrul, Inhaled PLGA Particles of Prostaglandin E1 Ameliorate Symptoms and Progression of Pulmonary Hypertension at a Reduced Dosing Frequency, Molecular Pharmaceutics, 10, 5, 2013. Crossref

  15. Brunner Nathan, Perez Vinicio A. de Jesus, Richter Alice, Haddad François, Denault André, Rojas Vanessa, Yuan Ke, Orcholski Mark, Liao Xiaobo, Perioperative Pharmacological Management of Pulmonary Hypertensive Crisis during Congenital Heart Surgery, Pulmonary Circulation, 4, 1, 2014. Crossref

  16. Xu Hongfei, Ji Hongyu, Li Zerong, Qiao Wenmei, Wang Chenghao, Tang Jingling, In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery, International Journal of Nanomedicine, Volume 16, 2021. Crossref

  17. Al-Hilal Taslim A., Hossain Mohammad Anwar, Alobaida Ahmed, Alam Farzana, Keshavarz Ali, Nozik-Grayck Eva, Stenmark Kurt R., German Nadezhda A., Ahsan Fakhrul, Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects, Journal of Controlled Release, 334, 2021. Crossref

  18. Mohamed Nura A., Marei Isra, Crovella Sergio, Abou-Saleh Haissam, Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases, International Journal of Molecular Sciences, 23, 3, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain